Peterson Katharine has filed 12 insider transactions across 1 company since May 2024.
Most recent transaction: a grant/award of 14227 shares of Acrivon Therapeutics, Inc. ($ACRV) on May 18, 2026.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | A | Common Stock | 14227 | $0.00 | 18,134.0000 | 38,560,464 | 364.14% | 0.04% |
| May 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 99 | $1.92 | 3,907.0000 | 38,560,464 | 2.47% | 0.00% |
| March 1, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | A | Stock Option (Right to Buy) | 31900 | $0.00 | 31,900.0000 | 38,560,464 | 9999.99% | 0.08% |
| Feb. 14, 2026 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 116 | $1.63 | 4,006.0000 | 38,560,464 | 2.81% | 0.00% |
| Nov. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 99 | $2.24 | 4,122.0000 | 38,560,464 | 2.35% | 0.00% |
| Aug. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 99 | $1.39 | 4,221.0000 | 33,791,817 | 2.29% | 0.00% |
| May 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 99 | $1.14 | 4,320.0000 | 33,791,817 | 2.24% | 0.00% |
| March 1, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | A | Stock Option (Right to Buy) | 31900 | $0.00 | 31,900.0000 | 33,791,817 | 9999.99% | 0.09% |
| Feb. 14, 2025 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 116 | $5.42 | 4,419.0000 | 33,791,817 | 2.56% | 0.00% |
| Nov. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 99 | $7.92 | 4,535.0000 | 38,105,131 | 2.14% | 0.00% |
| Aug. 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 99 | $7.02 | 4,634.0000 | 22,078,190 | 2.09% | 0.00% |
| May 14, 2024 | Acrivon Therapeutics, Inc. | $ACRV | Peterson Katharine | Chief Accounting Officer | F | Common Stock | 99 | $8.36 | 4,733.0000 | 22,078,190 | 2.05% | 0.00% |